Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem-Cell Transplant Determines the Kinetics of Acute Graft-Versus-Host Disease

Background. Preparative myeloablative conditioning regimens for allogeneic hematopoietic stem-cell transplantation (HSCT) may control malignancy and facilitate engraftment but also contribute to transplant related mortality, cytokine release, and acute graft-versus-host disease (GVHD). Reduced intensity conditioning (RIC) regimens have decreased transplant related mortality but the incidence of acute GVHD, while delayed, remains unchanged. There are currently no in vivo allogeneic models of RIC HSCT, limiting studies into the mechanism behind RIC-associated GVHD. Methods. We developed two RIC HSCT models that result in delayed onset GVHD (major histocompatibility complex mismatched (UBI-GFP/BL6 [H-2b]→BALB/c [H-2d]) and major histocompatibility complex matched, minor histocompatibility mismatched (UBI-GFP/BL6 [H-2b]→BALB.B [H-2b])) enabling the effect of RIC on chimerism, dendritic cell (DC) chimerism, and GVHD to be investigated. Results. In contrast with myeloablative conditioning, we observed that RIC-associated delayed-onset GVHD is characterized by low production of tumor necrosis factor-α, maintenance of host DC, phenotypic DC activation, increased T-regulatory cell numbers, and a delayed emergence of activated donor DC. Furthermore, changes to the peritransplant milieu in the recipient after RIC lead to the altered activation of DC and the induction of T-regulatory responses. Reduced intensity conditioning recipients suffer less early damage to GVHD target organs. However, as donor cells engraft, activated donor DC and rising levels of tumor necrosis factor-α are associated with a later onset of severe GVHD. Conclusions. Delineating the mechanisms underlying delayed onset GVHD in RIC HSCT recipients is vital to improve the prediction of disease onset and allow more targeted interventions for acute GVHD.

[1]  C. Shieh,et al.  The functional insufficiency of human CD4+CD25high T‐regulatory cells in allergic asthma is subjected to TNF‐α modulation , 2007, Allergy.

[2]  S. Keshav Faculty Opinions recommendation of Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. , 2007 .

[3]  M. Fujimoto,et al.  CD83 Expression Is a Sensitive Marker of Activation Required for B Cell and CD4+ T Cell Longevity In Vivo1 , 2007, The Journal of Immunology.

[4]  D. Männel,et al.  Interaction of TNF with TNF Receptor Type 2 Promotes Expansion and Function of Mouse CD4+CD25+ T Regulatory Cells1 , 2007, The Journal of Immunology.

[5]  M. Sykes,et al.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. , 2007, Blood.

[6]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[7]  J. Lau,et al.  Activated Circulating Dendritic Cells After Hematopoietic Stem Cell Transplantation Predict Acute Graft-Versus-Host Disease , 2007, Transplantation.

[8]  W. Murphy,et al.  Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.

[9]  C. Contag,et al.  In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. , 2007, Blood.

[10]  J. Ferrara Novel strategies for the treatment and diagnosis of graft-versus-host-disease. , 2007, Best practice & research. Clinical haematology.

[11]  N. Amariglio,et al.  α1β1 Integrin+ and Regulatory Foxp3+ T Cells Constitute Two Functionally Distinct Human CD4+ T Cell Subsets Oppositely Modulated by TNFα Blockade1 , 2007, The Journal of Immunology.

[12]  N. Amariglio,et al.  alpha1beta1 Integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFalpha blockade. , 2007, Journal of Immunology.

[13]  J. Kasir,et al.  Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation? , 2006, Bone Marrow Transplantation.

[14]  Charles P. Lin,et al.  An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues , 2006, The Journal of experimental medicine.

[15]  A. Barrett,et al.  Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents , 2006, Leukemia.

[16]  W. Selby,et al.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.

[17]  P. Lipsky,et al.  TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.

[18]  G. Adema,et al.  Dendritic Cells Activated by Lipopolysaccharide after Dexamethasone Treatment Induce Donor-Specific Allograft Hyporesponsiveness , 2006, Transplantation.

[19]  S. Mackinnon,et al.  The fate of human Langerhans cells in hematopoietic stem cell transplantation , 2006, The Journal of experimental medicine.

[20]  A. Dickinson,et al.  In Vitro Depletion of Tissue-Derived Dendritic Cells by CMRF-44 Antibody and Alemtuzumab: Implications for the Control of Graft-Versus-Host Disease , 2005, Transplantation.

[21]  Jiang Zhu,et al.  Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease1 , 2005, The Journal of Immunology.

[22]  D. Jain,et al.  Donor APCs are required for maximal GVHD but not for GVL , 2004, Nature Medicine.

[23]  U. Duffner,et al.  Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-versus-Host Disease1 , 2004, The Journal of Immunology.

[24]  T. Koike,et al.  Unexpected role of TNF-α in graft versus host reaction (GVHR) : donor-derived TNF-α suppresses GVHR via inhibition of IFN-γ-dependent donor type-1 immunity , 2004 .

[25]  Irving L Weissman,et al.  Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease , 2004, Nature Medicine.

[26]  S. Mackinnon,et al.  Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. , 2004, Blood.

[27]  A. Bacigalupo Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus , 2004, Bone Marrow Transplantation.

[28]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[29]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[30]  R. Korngold,et al.  Role of tumor necrosis factor-α in graft-versus-host disease and graft-versus-leukemia responses , 2003 .

[31]  Stephen C. Jones,et al.  Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  G. Gorgun,et al.  Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  R. Korngold,et al.  Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  G. Amir,et al.  Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia , 2003, Bone Marrow Transplantation.

[35]  S. Ikehara,et al.  Optimal protocol for total body irradiation for allogeneic bone marrow transplantation in mice , 2002, Bone Marrow Transplantation.

[36]  M. Taniguchi,et al.  Immune Tolerance to Combined Organ and Bone Marrow Transplants After Fractionated Lymphoid Irradiation Involves Regulatory NK T Cells and Clonal Deletion1 , 2002, The Journal of Immunology.

[37]  C. Fathman,et al.  Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.

[38]  David Klatzmann,et al.  CD4+CD25+ Immunoregulatory T Cells , 2002, The Journal of experimental medicine.

[39]  R. Chakraverty,et al.  Role of dendritic cells in graft-versus-host disease. , 2002, Journal of hematotherapy & stem cell research.

[40]  Jiang Zhu,et al.  Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. , 2002, The Journal of clinical investigation.

[41]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[42]  N. Russell,et al.  Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. , 2002, Blood.

[43]  I. Lossos,et al.  Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. , 2002, Blood.

[44]  C. Craddock,et al.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. , 2002, Blood.

[45]  P. Marrack,et al.  Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo. , 2001, Cellular immunology.

[46]  R. Iannone,et al.  Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. , 2001, Blood.

[47]  P. Huie,et al.  Predominance of NK1.1+TCRαβ+ or DX5+TCRαβ+ T Cells in Mice Conditioned with Fractionated Lymphoid Irradiation Protects Against Graft-Versus-Host Disease: “Natural Suppressor” Cells1 , 2001, The Journal of Immunology.

[48]  R. Noelle,et al.  Cd4+Cd25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade , 2001, The Journal of experimental medicine.

[49]  P. Huie,et al.  Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. , 2001, Journal of immunology.

[50]  M. Eckhaus,et al.  An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[51]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[52]  D. Hart,et al.  Dendritic cells: unique leukocyte populations which control the primary immune response. , 1997, Blood.

[53]  J. Crawford,et al.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. , 1997, Blood.

[54]  R. Renkonen Immunobiology of acute graft-versus-host disease. , 1987, Medical biology.

[55]  The role of antigen-presenting cells. , 1983, Transplantation proceedings.

[56]  S. Strober,et al.  Allogeneic marrow transplantation after total lymphoid irradiation (TLI): effect of dose/fraction, thymic irradiation, delayed marrow infusion, and presensitization. , 1979, Journal of immunology.